{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:32:41Z","timestamp":1792661561017,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018592","name":"Celltrion Pharm Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clinthera.2025.08.003","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T09:44:52Z","timestamp":1757756692000},"page":"159-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Azilsartan Medoxomil and Amlodipine Combination Therapy in Patients With Mild-to-Moderate Essential Hypertension Inadequately Controlled on Monotherapy"],"prefix":"10.1016","volume":"48","author":[{"given":"Dae-Hee","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Ah","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moo Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Ju","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Miekus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzung-Dau","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Pei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-478X","authenticated-orcid":false,"given":"Sungha","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.08.003_bib0001","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/HYPERTENSIONAHA.119.14240","article-title":"High blood pressure and cardiovascular disease","volume":"75","author":"Fuchs","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0002","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk: a compass for future health","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0003","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"289","key":"10.1016\/j.clinthera.2025.08.003_sbref0005","first-page":"1","article-title":"Hypertension prevalence and control among adults: United States, 2015-2016","author":"Fryar","year":"2017","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0006","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","article-title":"Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries","volume":"134","author":"Mills","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0007","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","article-title":"Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials","volume":"122","author":"Wald","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0008","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0009","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","article-title":"Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial","volume":"398","author":"Chow","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40885-023-00234-9","article-title":"The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Hypertens"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2016-000473","article-title":"Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes","volume":"3","author":"Fares","year":"2016","journal-title":"Open Heart"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0012","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/MBP.0000000000000027","article-title":"Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension","volume":"19","author":"Weber","year":"2014","journal-title":"Blood Press Monit"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0013","first-page":"634","article-title":"Azilsartan medoxomil (Edarbi): the eighth angiotensin II receptor blocker","volume":"36","author":"Jones","year":"2011","journal-title":"P t"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0014","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40256-022-00521-0","article-title":"Perindopril\/indapamide\/amlodipine in hypertension: a profile of its use","volume":"22","author":"Syed","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1185\/03007990802597456","article-title":"Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies","volume":"25","author":"Ram","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0016","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1751-7176.2011.00437.x","article-title":"A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil \u00b1 hydrochlorothiazide","volume":"13","author":"Weir","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0017","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1751-7176.2010.00422.x","article-title":"Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity","volume":"13","author":"Punzi","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0018","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.110.163402","article-title":"Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension","volume":"57","author":"White","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0019","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/hr.2012.8","article-title":"Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study","volume":"35","author":"Rakugi","year":"2012","journal-title":"Hypertens Res"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0020","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/hr.2014.118","article-title":"Possible benefits of azilsartan compared with other angiotensin II type 1 receptor blockers","volume":"37","author":"Miura","year":"2014","journal-title":"Hypertens Res"},{"key":"10.1016\/j.clinthera.2025.08.003_sbref0021","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-3758(01)00077-5","article-title":"Optimally weighted, fixed sequence and gatekeeper multiple testing procedures","volume":"99","author":"Westfall","year":"2001","journal-title":"J Stat Plan Inference"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0022","article-title":"Comparison of Efficacy and Safety of Azilsartan and Amlodipine Combination Versus Telmisartan and Amlodipine Combination in Hypertensive Patients: a Non-inferiority Trial","volume":"15","author":"Dash","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0023","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0024","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0025","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","article-title":"Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0026","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002276","article-title":"Reducing the blood pressure-related burden of cardiovascular disease: impact of achievable improvements in blood pressure prevention and control","volume":"4","author":"Hardy","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.clinthera.2025.08.003_sbref0027","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archinte.1995.00430070053006","article-title":"Implications of small reductions in diastolic blood pressure for primary prevention","volume":"155","author":"Cook","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0028","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1742-1241.2008.01977.x","article-title":"The combination of amlodipine\/valsartan 5\/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg","volume":"63","author":"Schrader","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2025.08.003_bib0029","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/jch.13272","article-title":"The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis","volume":"20","author":"Du","year":"2018","journal-title":"J Clin Hypertens (Greenwich)"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:44:05Z","timestamp":1772840645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825002851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0149291825002851"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.08.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Azilsartan Medoxomil and Amlodipine Combination Therapy in Patients With Mild-to-Moderate Essential Hypertension Inadequately Controlled on Monotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}